No connection

Search Results

ABBV vs KYNB

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
KYNB
Kyntra Bio, Inc.
BEARISH
Price
$7.17
Market Cap
$29.0M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ABBV
163.63
KYNB
--
Forward P/E
ABBV
15.42
KYNB
-0.7
P/B Ratio
ABBV
-146.66
KYNB
-0.97
P/S Ratio
ABBV
6.5
KYNB
4.51
EV/EBITDA
ABBV
15.27
KYNB
0.13

Profitability

Gross Margin
ABBV
71.46%
KYNB
-273.8%
Operating Margin
ABBV
35.5%
KYNB
-1058.65%
Profit Margin
ABBV
4.0%
KYNB
2848.63%
ROE
ABBV
137.96%
KYNB
--
ROA
ABBV
9.59%
KYNB
-16.96%

Growth

Revenue Growth
ABBV
9.1%
KYNB
-59.3%
Earnings Growth
ABBV
-88.7%
KYNB
--

Financial Health

Debt/Equity
ABBV
--
KYNB
4.37
Current Ratio
ABBV
0.72
KYNB
3.39
Quick Ratio
ABBV
0.47
KYNB
3.19

Dividends

Dividend Yield
ABBV
3.05%
KYNB
--
Payout Ratio
ABBV
490.15%
KYNB
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
KYNB BEARISH

KYNB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio (-0.97), indicating that liabilities exceed assets. While the company maintains a healthy current ratio (3.39), the underlying fundamentals are deteriorating with a YoY revenue decline of 59.30% and a catastrophic 5-year price depreciation of 98.6%. The reported profit margin is a mathematical anomaly likely driven by a one-time non-operating gain, as the operating margin remains deeply negative at -1058.65%. Despite a lone analyst's aggressive price target of $43.00, the deterministic data suggests a high risk of insolvency or further dilution.

Strengths
Strong short-term liquidity (Current Ratio 3.39)
Quick ratio (3.19) suggests sufficient liquid assets for immediate obligations
Recent 1-year price performance is slightly positive (+10.3%)
Risks
Negative equity (Price/Book -0.97) indicating technical insolvency
Severe revenue contraction (-59.30% YoY)
Extremely poor financial health (Piotroski F-Score 1/9)

Compare Another Pair

ABBV vs KYNB: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Kyntra Bio, Inc. (KYNB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile